CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
REVENUES:
Total Revenues	$ 2,728	$ 1,425
OPERATING EXPENSES:
Research and Development	11,695	11,151
General and Administrative	3,666	4,896
Other Asset Impairment		1,800
Gain on Fair Value Remeasurement of Contingent Consideration	234	1,519
Total Operating Expenses	15,595	19,366
Operating Loss	(12,867)	(17,941)
Investment and Other Income, Net	242	702
Net Loss	$ (12,625)	$ (17,239)
Basic and Diluted Net Loss Per Common Share	$ (0.73)	$ (1.40)
Shares Used in Calculating Basic and Diluted Net Loss per Share	17,406	12,297
COMPREHENSIVE LOSS:
Net Loss	$ (12,625)	$ (17,239)
Other Comprehensive Income (Loss):
Unrealized Gain on Marketable Securities	(22)	19
Comprehensive Loss	(12,647)	(17,220)
Product Development and Licensing Agreements
REVENUES:
Total Revenues	2,286	129
Contracts and Grants
REVENUES:
Total Revenues	$ 442	$ 1,296